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Abstract
Pigs are often colonized by more than one bacterial and/or viral species during respiratory tract infections. This
phenomenon is known as the porcine respiratory disease complex (PRDC). Actinobacillus pleuropneumoniae (App) and
porcine reproductive and respiratory syndrome virus (PRRSV) are pathogens that are frequently involved in PRDC. The main
objective of this project was to study the in vitro interactions between these two pathogens and the host cells in the
context of mixed infections. To fulfill this objective, PRRSV permissive cell lines such as MARC-145, SJPL, and porcine alveolar
macrophages (PAM) were used. A pre-infection with PRRSV was performed at 0.5 multiplicity of infection (MOI) followed by
an infection with App at 10 MOI. Bacterial adherence and cell death were compared. Results showed that PRRSV pre-
infection did not affect bacterial adherence to the cells. PRRSV and App co-infection produced an additive cytotoxicity
effect. Interestingly, a pre-infection of SJPL and PAM cells with App blocked completely PRRSV infection. Incubation of SJPL
and PAM cells with an App cell-free culture supernatant is also sufficient to significantly block PRRSV infection. This antiviral
activity is not due to LPS but rather by small molecular weight, heat-resistant App metabolites (,1 kDa). The antiviral
activity was also observed in SJPL cells infected with swine influenza virus but to a much lower extent compared to PRRSV.
More importantly, the PRRSV antiviral activity of App was also seen with PAM, the cells targeted by the virus in vivo during
infection in pigs. The antiviral activity might be due, at least in part, to the production of interferon c. The use of in vitro
experimental models to study viral and bacterial co-infections will lead to a better understanding of the interactions
between pathogens and their host cells, and could allow the development of novel prophylactic and therapeutic tools.
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Introduction
Respiratory disease in pigs is common in modern pork
production worldwide and is often referred to as porcine
respiratory disease complex (PRDC) [1]. PRDC is polymicrobial
in nature, and occurs following infections with various combina-
tions of primary and secondary respiratory pathogens. There are a
variety of viral and bacterial pathogens commonly associated with
PRDC including porcine reproductive and respiratory syndrome
virus (PRRSV) and Actinobacillus pleuropneumoniae (App) [1]. Both are
considered pathogens of major importance or relevance for the pig
industry [1]. Furthermore, bacterial-viral co-infections can exac-
erbate the pathogenicity of respiratory pig diseases [1]. For
example, co-infections with Mycoplasma hyopneumoniae and swine
influenza virus (SIV) exhibited more severe clinical disease [2],
PRRSV and Streptococcus suis co-infection experiments confirmed
that PRRSV predisposes pigs to S. suis infection and bacteremia
[3] and increases the virulence of PRRSV in pigs [4], M.
hyopneumoniae infection increases effectiveness of PRRSV infection
and lesions [5], and PRRSV infection was able to accelerate
Haemophilus parasuis infection and loads [6]. Those studies on co-
infections principally looked at the macroscopic lesions and at the
clinical signs. Only a few recent studies are investigating more
closely the direct interactions and mechanisms involved between
the pathogens. As an example, Qiao and collaborators showed
that PRRSV and bacterial endotoxin (LPS) act in synergy to
amplify the inflammatory response of infected macrophages [7].
Thus, it is crucial to develop new in vitro models to investigate in
more details the mechanistic and the interactions involved in
polymicrobial infections.
Porcine reproductive and respiratory syndrome (PRRS) is the
most economically devastating viral disease affecting the swine
industry worldwide [8]. The etiological agent, PRRSV, possesses a
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RNA viral genome with ten open reading frames [8–10]. PRRSV
virulence is multigenic and resides in both the non-structural and
structural viral proteins. The molecular characteristics, biological
and immunological functions of the PRRSV structural and non-
structural proteins and their involvement in the virus pathogenesis
were recently reviewed [8]. The disease induced by PRRSV has
many clinical manifestations but the two most prevalent are severe
reproductive failure in sows and gilts (characterized by late-term
abortions, an increased number of stillborn, mummified and weak-
born pigs) [11,12] and respiratory problems in pigs of all ages
associated with a non-specific lymphomononuclear interstitial
pneumonitis [11–13].
App is the causative agent of porcine pleuropneumonia, a severe
and highly contagious respiratory disease responsible for major
economic losses in the swine industry worldwide [14]. The disease,
transmitted by aerosol or by direct contact with infected pigs, may
result in rapid death or in severe pathology characterized by
hemorrhagic, fibrinous, and necrotic lung lesions. Exposure to the
organism may lead to chronic infection such that animals fail to
thrive; alternatively, they survive as asymptomatic carriers that
transmit the disease to healthy herds. Many virulence factors of
this microorganism have been well characterized [14–16]. To
date, fifteen serotypes of App based on capsular antigens have been
described [17,18]. The prevalence of specific serotypes varies with
geographic region [17].
Recent advances in pathogen detection methods allow better
understanding of interactions between pathogens, improve char-
acterization of their mechanisms in disease potentiation and
demonstrate the importance of polymicrobial disease [1]. In the
present study, the in vitro interactions between PRRSV and App in
PRRSV permissive cell models were investigated. Thus, MARC-
145 cells, SJPL cell line and pulmonary alveolar macrophages
(PAM) were used in this study since they have been shown
previously to be permissive to PRRSV infection and replication
[8,19]. Results indicate that App possesses a strong antiviral activity
against PRRSV in vitro.
Results
PRRSV Infection Effect on App Bacterial Adherence
Bacterial adherence of Appwt and AppDapxIDapxIIC to PRRSV-
infected and non-infected SJPL and MARC-145 cells was
compared (Figure 1). Prior infection of both cell types with
PRRSV did not significantly affect the adhesion of neither Appwt
nor AppDapxIDapxIIC strain.
Impact of App and PRRSV Co-infection on Cell
Cytotoxicity
Auger et al. 2009 [20] have previously published that SJPL cell
death induced by App occurs through necrosis and not apoptosis.
Consequently, based on this previous report, only a cytotoxicity
experiment was performed in order to verify if PRRSV infection
increases the cytotoxicity of App. Moreover, this assay was done to
confirm that inactivation of the toxins ApxI and ApxII in the
mutant AppDapxIDapxIIC reduces cell death seen with Appwt strain.
Thus, LDH cytotoxicity assays to detect cell death were performed
on cells infected with PRRSV for 72 hours and then co-infected
with Appwt strain or AppDapxIDapxIIC. As shown in Figure 2, the
cytotoxic activity of Appwt was higher in both cell lines after 2
hours of incubation, around 36% in SJPL cells (Figure 2A) and
around 14% in MARC-145 cells (Figure 2C) compared to the one
of AppDapxIDapxIIC mutant after 6 hours of incubation, which was
less than 15% in SJPL cells (Figure 2B) and around 7% in MARC-
145 cells (Figure 2D). As expected, the AppDapxIDapxIIC mutant is
markedly less cytotoxic than the parental strain Appwt. Thus,
AppDapxIDapxIIC mutant allows much longer incubation periods
with cells and facilitate in vitro observation. Furthermore, co-
infection with PRRSV and AppDapxIDapxIIC increased SJPL and
MARC-145 cells death compared to App single infection (Figure 2B
and D, respectively), showing an additive cytotoxicity effect of
PRRSV and AppDapxIDapxIIC. Because of its markedly reduced
cytotoxicity, the AppDapxIDapxIIC was used for all the subsequent
experiments.
App Effects on PRRSV Infection
In SJPL cells, co-infection with AppDapxIDapxIIC and PRRSV
shows absence of PRRSV N viral protein detection by IFA
compared to control where SJPL cells were infected with PRRSV
alone (Figure 3A) suggesting an inhibition of PRRSV infection
and/or replication (Figure 3B). MARC-145 cell line was used to
compare results obtained with SJPL cell line since MARC-145
cells are the most common cells used during in vitro PRRSV
studies. Interestingly, results were different between the two cell
lines. In PRRSV infected MARC-145 cells, only a small reduction
of cells expressing the PRRSV N protein was observed following a
co-infection with AppDapxIDapxIIC (Figure 3G). Thus, SJPL cells
were qualitatively more responsive to the App antiviral affect than
MARC-145 cells. Moreover, since SJPL cells were recently shown
to be from monkey origin [21] and not from swine as first
described [22], evaluation of the antiviral activity of App was tested
in a porcine relevant cell model, the PAM cells. Co-infection with
AppDapxIDapxIIC and PRRSV in PAM cells also presented total
absence of PRRSV N protein detection (Figure 3L), as in SJPL
cells (Figure 3B), suggesting that AppDapxIDapxIIC can also inhibits
PRRSV in PRRSV’s in vivo porcine target cells, the porcine
alveolar macrophages. Incubation with UV-inactivated AppDapxI-
DapxIIC bacteria after PRRSV infection allowed the detection of
N proteins of PRRSV by IFA in all cell types (Figure 3C, 3H and
3M) showing that UV-inactivated bacteria were not able to block
PRRSV infection. Interestingly, the bacteria-free culture super-
natant of AppDapxIDapxIIC also effectively blocked PRRSV
infection in SJPL and PAM cells (Figure 3D and 3N, respectively).
A weak inhibition was observed in MARC-145 cells (Figure 3I).
pH did not vary between all the tested conditions, being stable at
around 7.360.1. The active metabolites present in the culture
supernatant did not seem to be App LPS (Figure 3E, 3J and 3O)
nor peptidoglycan fragments (assayed with NOD1 or NOD2
ligands) (Figure S1D and S1F, respectively). Dilutions of
AppDapxIDapxIIC supernatant showed a dose-dependent effect on
PRRSV’s detection by IFA. A 1:2 dilution resulted in twice as
much PRRSV N protein when observed with IFA (data not
shown). The loss of antiviral activity of AppDapxIDapxIIC
supernatant was observed with 1:10, 1:20 and 1:40 dilutions.
PRRSV titers were measured to confirm IFA observations and
to quantify the inhibitory effect of AppDapxIDapxIIC on PRRSV
infection. SJPL, MARC-145 and PAM cells were infected or
treated as described previously. In SJPL cells after 72 hours post
PRRSV infection, viral titer obtained was 6.25 log10 TCID50/ml
(Figure 4A), in MARC-145 cells, was 7.6 log10 TCID50/ml
(Figure 4B) and in PAM cells, 6.0 log10 TCID50/ml (Figure 4C).
Co-infection with AppDDapxIDapxIIC or treatment with its culture
supernatant blocked completely PRRSV replication (P,0.01) in
SJPL cells (Figure 4A). But in MARC-145 cells, their antiviral
effect on PRRSV replication was markedly less efficient. More
specifically, in MARC-145 cells, PRRSV titers were 4.9 log10
TCID50/ml (which correspond to a 751 fold decrease compared to
PRRSV non-treated infected cell) and 6.5 log10 TCID50/ml
(which correspond to a 19 fold decrease compared to PRRSV
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non-treated infected cell) for AppDapxIDapxIIC (P,0.01) and its
cell-free culture supernatant (P,0.05) treated cells, respectively
(Figure 4B). In PAM cells, results obtained with PRRSV’s titration
showed that live AppDapxIDapxIIC completely blocked PRRSV
replication (P,0.001) and that its culture supernatant significantly
inhibits PRRSV infection in PAM, reducing its amount of
infectious virions to 2.9 log10 TCID50/ml (P,0.001 compared
to PRRSV infection at 106 TCID50/mL) which correspond to a
1250 fold decrease (Figure 4C). Stimulation of the cells with App
purified LPS or co-infection with UV inactivated bacteria did not
have any effect on PRRSV titer in all cell types (Figure 4A, 4B and
4C). Those results confirm the IFA data obtained previously. In
addition, it is important to note that inhibition in PAM is total with
live AppDapxIDapxIIC as observed previously in SJPL cells and
below PRRSV inoculum when treated with AppDapxIDapxIIC cell
culture supernatant. Thus, those results indicate that AppDapxI-
DapxIIC antiviral effect against PRRSV can be observed not only
in SJPL cells but also in porcine alveolar macrophages.
Figure 1. Bacterial adherence over time of Appwt or AppDapxIDapxIIC in PRRSV co-infected SJPL and MARC-145 cells. SJPL (A) and
MARC-145 (B) cells were infected with or without PRRSV at an MOI of 0.5 during 72 hours, and then cells were co-infected with Appwt or
AppDapxIDapxIIC at an MOI of 10. Bacterial adherence was measured in CFU per well after 1, 2 and 3 hours post bacterial infection as described in
Auger et al., 2009 [20]. Values are presented as 6 Standard Deviation (SD). No statistical significance was obtained following two-away ANOVA
analysis. All experiments were repeated 3 times.
doi:10.1371/journal.pone.0098434.g001
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Fractionation of Cell Culture Supernatant of
AppDapxIDapxIIC
Fractionation of the cell culture supernatant of AppDapxIDapxIIC
indicated that the ihnibitory effect on PRRSV infection is
mediated by small App metabolite(s) weighting ,1 kDa
(Figure 5C). The same results were obtained with all small
fractions tested, ,3 (Figure S2D), 10 (data not shown) and 50 kDa
(Figure S2F). Additionally, treatment at 56uC for 30 min of these
low molecular weight App metabolite(s) did not inactivate their
ihnibitory effect on PRRSV infection and/or replication in SJPL
cells, showing that those App antiviral metabolites are heat-
resistant (data not shown).
Antiviral Efficacy of AppDapxIDapxIIC Cell Culture
Supernatant against Several other Viruses
Since AppDapxIDapxIIC cell culture supernatant inhibits PRRSV
replication, other viruses were tested in order to verify if this
inhibition is virus specific or if it is a general antiviral effect. First,
the SJPL cells permissivity was tested in regards to different DNA
genome viruses such as: BAV3, BHV-1, BHV-4, CPV, EHV-1,
and PCV2; as well as RNA genome viruses such as: BVDV-1,
Influenza H1N1, and Influenza H3N2. BAV3, BHV-1, EHV-1,
BVDV-1, Influenza H1N1, and Influenza H3N2 viruses were able
to infect and replicate in SJPL cells (Table 1). Thus, treatment with
AppDapxIDapxIIC culture supernatant was performed after infec-
tion with those viruses in SJPL cells, to verify its spectrum of
antiviral activity. Overall, 50% of the viruses tested that are able to
replicate in SJPL cells (excluding PRRSV) were inhibited by
Figure 2. Cytotoxicity over time of Appwt or AppDapxIDapxIIC in PRRSV co-infected SJPL and MARC-145 cells. SJPL (A and B) and MARC-
145 cells (C and D) were infected with or without PRRSV at an MOI of 0.5 during 72 hours, and then cells were co-infected with App (for 1 or 2 hours)
(A and C, respectively) or with AppDapxIDapxIIC (for 4, 5 and 6 hours) (B and D, respectively) at an MOI of 10. Cytotoxicity was measured in % using
lactate dehydrogenase (LDH) CytoTox assay [20]. Values are presented as 6 Standard Deviation (SD). Two-away ANOVA analysis was used to obtain
statistical data. *P,0.05. All experiments were performed 3 times.
doi:10.1371/journal.pone.0098434.g002
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AppDapxIDapxIIC cell culture supernatant. Those inhibited viruses
were: EHV-1, Influenza H1N1 and H3N2. However, it is
important to note that the inhibition of PRRSV replication
observed following treatment with AppDapxICDapxIIC supernatant
was significantly higher compared to than the inhibition observed
against EHV-1, Influenza H1N1 and H3N2 (Table 1). These
results are important because they indicate that SJPL cells were
still able to allow the replication of several viruses in the presence
of AppDapxIDapxIIC cell culture supernatant, indicating that the
SJPL cells are still metabolically active and fit for viruses’
replication.
Effect of AppDapxIDapxIIC Cell Culture Supernatant on
the Mrna Level of Type I and Type II IFNs
Since the levels of mRNA expression of type I (IFNa and IFNb)
and type II (IFNc) interferons are known to be implicated in the
cellular antiviral effect against PRRSV [23–26], mRNA levels of
those cytokines were measured by qRT-PCR (Figure 6). No
modulation of IFNa was observed in any of the tested conditions,
including the Poly I:C control. This observation was also
previously made by Provost et al., 2012 [19]. PRRSV infection
in SJPL cells significantly increased IFNb levels compared to mock
infected cells, as previously described in Provost et al., 2012 [19].
Treatment with AppDapxICDapxIIC supernantant alone induced a
significant increase of IFNb mRNA compared to mock infected
cells, but co-treated cells did not showed a significant increase
compared to mock infected cells. PRRSV infection in SJPL cells
Figure 3. PRRSV antigen detection in SJPL, MARC-145 and PAM cells co-infected with AppDapxIDapxIIC. PRRSV N protein revealed by IFA
in SJPL (A–E), MARC-145 (F–J) and PAM cells (K–O) were infected with PRRSV at an MOI of 0.5 for 4 hours (A, F and K) then co-infected with live
AppDapxIDapxIIC at an MOI of 10 (B, G and L), or with UV inactivated AppDapxIDapxIIC at an MOI of 10 (C, H and M), or with AppDapxIDapxIIC
supernatant (D, I and N) or treated with LPS 4 mg/ml (E, J and O) for 48 hours. Inserts are negative control where cells were not infected with PRRSV.
White scale bar represents 200 mm for SJPL and MARC-145 cells, and 100 mm for PAM cells. Pictures were taken at 100X magnification for SJPL and
MARC-145 cells, and 200X for PAM cells.
doi:10.1371/journal.pone.0098434.g003
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did not modulate IFNc mRNA levels. However, treatment with
AppDapxICDapxIIC supernantant alone or as co-treatment signif-
icantly increased IFNc mRNA compared to mock infected SJPL
cells.
Discussion
Many studies have previously shown that respiratory viral
infections can increase bacterial adherence to cells. For example,
influenza A infection increases adherence of Streptococcus pyogenes to
MDCK cells [27], rhinovirus infection increases adherence of
Streptococcus pneumoniae to cultured human airway epithelial cells
[28], and respiratory syncytial virus (RSV), human parainfluenza
virus 3 (HPIV-3), and influenza virus increase the adherence of
Haemophilus influenzae and S. pneumoniae to respiratory epithelial cells
[29]. However, in the present study, no modulation of App
adherence was observed when cells were infected with PRRSV.
Appwt induced, as expected, a high percentage of cytotoxicity in
SJPL cells (Figure 2). Its derivative, AppDapxIDapxIIC, that is
expressing the non-activated toxins ApxI and ApxII, showed a
much lower cytotoxicity in SJPL cells. Furthermore, as previously
described in Provost et al. 2012, PRRSV infection in SJPL cells
induced a significant increase of cell death [19]. However, co-
infection with PRRSV and AppDapxIDapxIIC did not result in a
significant increase of cell death when compared to PRRSV
infection alone, supporting that AppDapxIDapxIIC is less (if not)
toxic to eukaryotic cells and that cytotoxicity is mainly caused by
PRRSV in co-infected cells. Interestingly, this less toxic App
mutant enables longer exposure in in vitro experiments and allowed
us to observe App’s antiviral effect on PRRSV.
The antiviral effect of AppDapxIDapxIIC was first observed on
SJPL cells co-infected with PRRSV (Figure 3). Subsequently, other
results showed that the antiviral activity was also present in the
Figure 4. PRRSV titer in App treated SJPL, MARC-145 and PAM
cells. SJPL (A), MARC-145 (B) and PAM (C) cells were infected with
PRRSV MOI of 0.5 for 4 hours and then co-infected with AppDapxI-
DapxIIC MOI of 10, or with UV inactivated AppDapxIDapxIIC MOI of 10,
or treated with LPS (4 mg/ml) or culture supernatant of AppDapxIDap-
xIIC for 48 hours. PRRSV titer was determined on MARC-145 cells by the
Ka¨rber method. Values are presented as 6 Standard Deviation (SD).
One-away ANOVA analysis was used to obtain statistical data. When
bars within a cell type are labeled with superscripts letters, it indicates
that these sets of data are statistically different from the other bars (P,
0.05).
doi:10.1371/journal.pone.0098434.g004
Figure 5. AppDapxIDapxIIC cell culture supernatant ,1 kDa
fraction antiviral activity against PRRSV. Detection of the N viral
protein in PRRSV infected SJPL cells by immunofluorescence. SJPL cells
were infected with 0.5 MOI of PRRSV for 4 hours then incubated with
DMEM culture medium alone (DMEM) (A) or either a DMEM culture
medium fraction of ,1 kDa (DMEM ,1 kDa) (B) or a AppDapxIDapxIIC
cell culture supernatant ,1 kDa fraction (App,1 kDa) (C) added to
complete SJPL culture medium for 48 hours. White scale bar represents
200 mm. Pictures were taken at 100X magnification.
doi:10.1371/journal.pone.0098434.g005
Inhibition of PRRS Virus Infection
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bacterial supernatant and was not due to App purified LPS, nor
NOD ligands, but probably to low molecular weight metabolites of
,1 kDa. Inhibition of PRRSV replication by AppDapxIDapxIIC is
not generated by contact between bacterial and eukaryotic host
cell, since it was also observed with App cell culture supernatant;
thus without the presence of App bacterial cells. Furthermore, this
antiviral effect is not only observed in SJPL cells but also in the
PRRSV natural host target cells, i.e. PAM. This suggests that the
antiviral action of AppDapxIDapxIIC can be efficient in different cell
species and types. Viral inhibition in PAM cells was complete in
presence of the bacteria AppDapxIDapxIIC and was partial when
treated with its cell culture supernatant. Other combinations of
Table 1. Antiviral activity of AppDapxIDapxIIC supernatant against several animal DNA and RNA viruses in SJPL infected cells.
Viruses Virus titer Relative virus replication inhibition
Without AppDapxIDapxIIC With AppDapxIDapxIIC
(TCID50 log10 ± SD)
DNA genome
BHV-4 Neg - -
CPV Neg - -
PCV2 Neg - -
BAV3 2.7560.35 2.8860.18 0.7462.45
BHV-1 4.5460.48 4.4260.59 1.3265.75
EHV-1 5.0060.71 3.7560.35 17.7866.17
RNA genome
BVDV-1 4.3860.18 4.2560.35 1.3562.45
H1N1 5.4060.57 4.2360.50* 14.865.75
H3N2 4.8560.50 3.8260.45** 10.7264.68
PRRSV 5.4460.56 1.6160.59*** 6760.8366.46a
All experiences were performed at least 2 times.
Statistical P value compared to AppDapxIDapxIIC untreated cells: P = 0.15.
Statistically significative compared to AppDapxIDapxIIC untreated cells: *P,0.05, **P,0.01, ***P,0.001.
Statistically significative compared to other viruses: aP,0.01.
doi:10.1371/journal.pone.0098434.t001
Figure 6. AppDapxIDapxIIC cell culture supernatant and PRRSV effects on mRNA quantification of type I (IFNa, IFNb) and type II
(IFNc) interferons. qRT-PCR results expressed in relative expression (DDCT) for IFNa (A), IFNb (B) and IFNc (C) in SJPL cells. The cells were mock
infected or infected with 0.5 MOI of PRRSV for 4 hours then treated without or with AppDapxICDapxIIC cell culture supernatant for 48 hours. Poly (I:C)
and LPS were used as positive controls. Data labeled with superscripts of different letters indicates that these sets of data are statistically different (P,
0.05).
doi:10.1371/journal.pone.0098434.g006
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treatments have been tested. Data obtained gave some informa-
tion about the mechanism of the antiviral activity of AppDapxI-
DapxIIC supernatant. Overall, they suggested that AppDapxIDap-
xIIC supernatant’s antiviral activity is not interfering with PRRSV
attachment and entry. Other experiments are currently in progress
to further investigate by which mechanisms the AppDapxIDapxIIC
supernatant is inhibiting PRRSV replication.
Despite the fact that MARC-145 and SJPL are of monkey
origin, they are phenotypically distinct as demonstrated by our
group in Provost et al. (2012) [19]. In this previous report, we
demonstrated that SJPL and MARC-145 cells do not have the
same division rate and that the development of the cytopathic
effect (CPE) induced by PRRSV in SJPL cells was delayed
compared to MARC-145 cells. Furthermore, the cytokine profiles
after PRRSV infection were different between the two cell lines.
These results suggested that PRRSV infection could be different in
each. Thus, the difference in PRRSV infection between both cell
lines could explain the difference observed for the AppDapxIDap-
xIIC supernatant antiviral activity.
Type I IFNs, produced by many cell types, are part of the innate
immunity response [30]. Moreover, it is well known in the
literature that type I IFNs are often part of the cellular response
against viral infections, including PRRSV infections [23,25].
Results of this study showed that there is no modulation of IFNa
mRNA levels. IFNb mRNA levels were increased in PRRSV and
in AppDapxIDapxIIC supernatant alone but no significant increase
was observed in the PRRSV + AppDapxIDapxIIC supernatant
condition when compared to mock infected cells. Thus, the
impaired IFNb expression following co-treatment might be due to
PRRSV replication which might block IFN production induced by
AppDapxIDapxIIC supernatant. Additionally, those results demon-
strate that since PRRSV can inhibit type I IFN induction and
signalling [31–34], antiviral activity induced by AppDapxIDapxIIC
supernatant may not rely on its ability to induce IFNb. However,
this does not mean that IFNb is not part of the antiviral activity of
AppDapxIDapxIIC supernatant, since most viruses are still sensitive
to type I IFNs.
Type II IFNc, mainly produced by activated T cells and
Natural Killer cells, is mostly responsible for adaptive Th1
response, which is part of cell-mediated immunity [35]. Further-
more, its implication in antiviral response against PRRSV was also
demonstrated [24,26]. Nonetheless, IFNc mRNA levels in SJPL
cells were significantly increased by AppDapxIDapxIIC supernatant
alone and in PRRSV + AppDapxIDapxIIC supernatant condition.
This observation might give a clue by which cellular response
AppDapxIDapxIIC supernatant induces its antiviral effect; i.e. via
the increased of IFNc mRNA levels by the cell. However, it is
important to mention that it is not known if SJPL cells possess
IFNc receptors, which are necessary for IFNc mediated signalling.
Further investigations are needed to confirm this hypothesis.
PRRSV can lead to persistent infections [36,37] and current
PRRSV vaccines are not yet optimal, since they lack the ability to
induce a strong immune response and since they do not provide
complete immunity against homologous PRRSV infections (for
review see [38,39]). Moreover, most PRRSV vaccines are live
attenuated virus and thus present a safety issue; some vaccinated
pigs were shown to produce shedding of virulent PRRSV particles
[40]. Thus, it is important to further investigate new possible ways
to control PRRSV infections. In that regards, an antiviral
molecule or metabolite might be a good alternative to the
currently used vaccines. Recently published studies showed few
compounds that can inhibits PRRSV as glycosides, terpenoids,
coumarins, isoflavones, peptolides, alkaloids, flavones, macrolides
[41], N-acetylpenicillamine [42], cyclosporine A [43], sodium
tanshinone IIA sulfonate [44], flavaspidic acid AB [45], Ribavirin
[46], and morpholino oligomer [47], or compounds derived from
plant as a polysaccharide isolated from Achyranthes bidentata [48] or
a mushroom extract from Cryptoporus volvatus [49]. However, there
is no commercially available antiviral drug against PRRSV on the
market.
In conclusion, to the best of our knowledge, this is the first
description of an App antiviral activity. This study might lead to the
development of a new treatment against PRRSV derived from App
cell culture supernatant. However, more investigations are needed
to identify and/or purify the target metabolite(s) secreted by App
before generating a possible new antiviral molecule against
PRRSV. Moreover, since we have demonstrated that the antiviral
effect of the metabolite(s) secreted from App is not only specific to
PRRSV, but also effective against other RNA viruses, this antiviral
activity might as well lead to a new antiviral treatment. For
example, molecules such as Ribavirin, which is currently used
against human respiratory syncytial virus (RSV) [50,51] and
hepatitis C infection [52], was initially demonstrated to have a
broad antiviral activity against animal viruses [53]. This study
might therefore allow the development of a new antiviral molecule
against PRRSV, but also against other viruses such as influenza.
Materials and Methods
Cells
All cells products were ordered from Invitrogen Corporation
GibcoBRL (Burlington, ON, CA) unless specified. MARC-145
cells, a subclone of African green monkey kidney MA104 cells,
were grown in minimum essential medium (MEM) supplemented
with 10% of foetal bovine serum (FBS) (Wisent Inc, St-Bruno, QC,
Canada), 0.1 mM HEPES, 2 mM L-glutamine, 10 U/mL of
penicillin, 10 mg/mL of streptomycin and 250 g/L antibiotic-
antimitotic solution [54]. The SJPL cell line (St. Jude porcine lung
epithelial cell) was provided by Dr. R.G. Webster (St. Jude
Children’s Hospital, Memphis, TN, USA) [22] and later was
demonstrated to be from monkey origin [21]. This cell line was
grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% FBS (Wisent Inc), 1 mM sodium pyruvate,
2 mM L-glutamine, 1 mM MEM nonessential amino acid, 10 U/
mL of penicillin, 10 mg/mL of streptomycin and 250 g/L
antibiotic-antimitotic solution and, 100 mg/L gentamicin. Porcine
alveolar macrophages (PAM) were harvested from lungs of 2 to 14
weeks old pigs as described previously [19]. Pigs were sacrificed
following ethic protocol 12-Rech-1640 approved by our institu-
tional ethic committee (Comite´ d’e´thique de l’utilisation des
animaux – CE´UA) following the guidelines of the Canadian
Council on Animal Care. Briefly, an instillation of the lungs with
PBS containing 10 units/mL penicillin, 10 mg/mL streptomycin
and 100 mg/L gentamicin was realized. Then, phosphate buffer
saline solution (PBS) was collected and PAM removed following
low speed centrifugation. Cells were washed with DMEM medium
complemented with 2 mM L-glutamine, 0,1 mM HEPES, 1 mM
non-essential amino acids, 250 g/L amphotericin B (Wisent Inc),
10 units/mL penicillin, 10 mg/mL streptomycin and 100 mg/L
gentamicin. Cells were then collected following low speed
centrifugation and were resuspended in freezing medium (same
as wash medium plus 20% foetal bovine serum and 10% DMSO
(Sigma-Aldrich, St-Louis, MO, USA)) and slowly frozen, than
stored in liquid nitrogen until further utilization. PAM cells were
cultured for 24 hours in complete DMEM prior to assay. All cells
were cultured and infected at 37uC in 5% CO2 atmosphere.
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Bacterial and Viral Strains
The App strains used in this study were the S4074 serotype 1
reference wild type strain (Appwt) and a mutant of this strain
(MBHPP147) producing non-active ApxI and ApxII toxins
(AppDapxICDapxIIC), kindly provided by Ruud P.A.M. Segers
(MSD Animal Health, Boxmeer, The Netherlands). App strains
were cultured on brain heart infusion (BHI) broth and/or agar
(Gibco) supplemented with 15 mg/ml nicotinamide adenine
dinucleotide (NAD) at 37uC in 5% CO2. The PRRSV strain
used in this study was the Canadian genotype II reference strain
IAF-Klop [55].
Adherence Assay
For the adherence assay, 105 epithelial cells/well were seeded
into 24 well-tissue culture plates (Sarstedt, Numbrecht, Germany)
and incubated overnight (O/N). Cells were infected with PRRSV
at 0.5 multiplicity of infection (MOI; virus particles or bacterial
cells per cell). Appwt and AppDapxIDapxIIC from an overnight
culture grown at an OD600 nm of 0.6 were resuspended in
complete cell culture medium to a concentration of 106 CFU/ml.
One ml of either suspension was added to each well at an MOI of
10 after 72 hours PRRSV infection, and plates were incubated for
1, 2 or 3 hours. Non-adherent bacteria were removed by washing
four times with Dulbecco’s Phosphate-Buffered Saline (DPBS)
(Gibco). Cells with adherent bacteria were released from the wells
by adding 100 ml of 1X trypsin-EDTA (Gibco) and resuspended in
900 ml DPBS buffer. Serial dilutions were performed and poured
on agar plates to determine the number of bacteria that adhered to
the epithelial cells. Bacteria colonies were counted as colonies
forming unit per well (CFU/well) as described by Auger et al., 2009
[20].
Cytotoxicity Detection Assay
For the cytotoxicity detection assay, 105 epithelial cells/wells
were seeded into 24 well-tissue culture plates (Sarstedt) and
incubated O/N. Cells were infected with PRRSV at 0.5 MOI.
Appwt and AppDapxIDapxIIC from an overnight culture grown at an
OD600 nm of 0.6 were resuspended in complete cell culture
medium to a concentration of 106 CFU/ml. One ml of either
suspension was added to each well at an MOI of 10 after 72 hours
PRRSV infection, and plates were incubated for 1 or 2 hours with
Appwt or for 4, 5 and 6 hours with AppDapxIDapxIIC. The cellular
cytotoxicity was determined using the lactate dehydrogenase
(LDH)-measuring CytoTox 96 nonradioactive cytotoxicity assay
(Promega, Madison, WI) as described by the manufacturer.
Noninfected cells were used as a negative control, while total cell
lysate was used for the 100%-cytotoxicity positive control, since all
LDH is released when cells are mechanically lysed. Optical
densities were measured at 490 nm with a Power Wave X340
(Biotek Instruments Inc, Winooski, VT) microplate reader and
used to calculate the percentage of cytotoxicity [55].
Immunofluorescence Assay
The presence of PRRSV antigens in infected cells was
determined by an immunofluorescence assay (IFA). Cells were
infected or treated as described below. Following treatment and/
or infections, cells were fixed with a 4% paraformaldehyde (PFA)
solution prepared as previously described [19]. Mock-infected or
non-treated cells were used as negative controls. After an
incubation period of 20 minutes at room temperature, the PFA
solution was removed and cells were washed three times with
Phosphate buffer solution (PBS). Then, cells were incubated
during 10 minutes at room temperature with a PBS solution
containing 0.1% Triton X-100 for cell membrane permeabiliza-
tion. After removing the Triton X-100 solution, cells were washed
three times with a PBS-Tween 20 solution (PBS containing 0.02%
Tween 20). Thereafter, cells were incubated 30 minutes with PBS
containing 0.02% Tween 20 and 1% foetal bovine serum albumin.
Then, the a7 rabbit monospecific antisera (anti-N PRRSV
protein) [55] was diluted 1/100 in the blocking solution and
added to the cells and incubated at 37uC for 90 minutes. Cells
were then washed and incubated for 60 minutes with the blocking
solution containing a 1/160 dilution of anti-rabbit specific
antiserum FITC conjugated (Sigma). Finally, cells were visualized
using a DMI 4000B reverse fluorescence microscope, image of the
cells were taken with a DFC 490 digital camera and the images
were analyzed using the Leica Application Suite Software, version
2.4.0 (Leica Microsystems Inc., Richmond Hill, Canada).
Antiviral Activity of AppDapxIDapxIIC Against PRRSV
Cells were infected with 0.5 MOI of PRRSV and incubated in
DMEM without serum or other additives for 4 hours, then all non-
attached virus were removed from the medium with soft washing
step using PBS. Thereafter fresh medium was added. AppDapxI-
DapxIIC from an overnight culture grown at an OD600 nm of 0.6
were resuspended at an MOI of 10 in complete cell culture
medium to a concentration of 106 CFU/ml. To obtain
AppDapxIDapxIIC UV inactivated, resuspended AppDapxIDapxIIC
at an MOI 100:1 were inactivated for 2 hours under UV light
(315 nm) in a rocking petri dish and their inactivation was
confirmed by plating on BHI-NAD. To obtain AppDapxIDapxIIC
supernatant, resuspended AppDapxIDapxIIC at an MOI of 10 were
centrifuged at 500 g for 15 minutes and harvested supernatants
were passed through a 0.22 mm filter to remove all residual
bacteria. Bacterial culture supernatants were further fractionated
through ultrafiltration membranes with cut-off of 50, 10, 3
(Amicon Ultra-15, Millipore, Billerica, MA) or 1 kDa (Macrosep
1K, Pall Life Sciences, Port Washington, NY) to obtain
AppDapxIDapxIIC cell culture supernatant fractions. AppDapxIDap-
xIIC supernatant was also diluted 1:2, 1:10, 1:20, 1:40. One ml of
the suspensions was added to each well 4 hours after PRRSV
infection, and plates were incubated for 48 hours. pH measure-
ments were performed directly in the wells of treated SJPL cells
using an Accumet basic AB15 pH meter (Fisher Scientific,
Ottawa, ON). The presence of PRRSV N antigen was determined
by IFA. The infectious dose of the virus was determined from
serial dilutions and calculated by the Ka¨rber method [56]. Briefly,
samples infected by PRRSV were subjected to three cycles of
freeze-thaw and cellular suspensions were then clarified by low
speed centrifugation at 1200 g for 10 minutes. Supernatants were
serially diluted then used to infect MARC-145 cells in a 96-well
tissue culture plate. The plate was incubated for 96 hours. Virus
titers were expressed in tissue culture infectious dose 50 per ml
(TCID50/ml). Presence of PRRSV was also evaluated by qRT-
PCR using a commercial kit (Tetracore Inc., Rockville, MD, USA)
as previously described [57].
Treatment with LPS and NOD Ligands
Cells were infected with PRRSV at 0.5 MOI of in DMEM
without serum and other additives and incubated for 4 hours.
Then infected cells were washed and fresh medium was added.
Cells were treated with 4 mg/ml of LPS purified from Appwt [58],
or 100 to 1,000 ng/ml of C12-iE-DAP (a NOD1 ligand,
InvivoGen, San Diego CA), or 100 to 1,000 ng/ml of L18-MDP
(a NOD2 ligand, InvivoGen) for 48 hours. The presence of
PRRSV N protein was determined by IFA. The virus titer was
determined as described above.
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App Cell Culture Supernatant Antiviral Activity Against
other DNA and RNA Viruses
The DNA genome viruses used in this experiment were: bovine
herpes virus type 4 (BHV-4) of strain FMV09-1180503; porcine
circovirus 2 (PCV2b) of strain FMV05–6302 and bovine
adenovirus 3 (BAV3); bovine herpes virus type 1 (BHV-1); canine
parvovirus (CPV); equine herpes virus type 1 (EHV-1). The RNA
genome viruses used in this experiment were: bovine viral diarrhea
virus type 1 (BVDV1) of strain NADL (ATCC VR-534); swine
influenza H1N1 of strain A/Swine/Saint-Hyacinthe/148/90 [59];
and Swine Influenza H3N2 of strain A/Swine/Quebec/4001/05
[60]. Cells were infected with each virus at different dilutions (1/
10; 1/100; 1/1000; 1/10000; 1/1000000; 1/10000000) for 4
hours in DMEM as described for PRRSV and than treated with
AppDapxIDapxIIC culture supernatant for 48 hours as described
above. The infectious dose of each virus was calculated as
described above for PRRSV using SJPL cells.
Analysis of Cytokine mRNAs Expression by Real Time
Reverse Transcriptase-quantitative PCR
SJPL cells and PAMs were treated and infected as described
above or transfected with Polyinosinic–polycytidylic acid potassi-
um salt (Poly (I:C)) [50 mg/mL] (Sigma-Aldrich Inc., St-Louis,
USA) as a positive control for innate immunity induction, using
polyethylenimine (PEI) [1 mg/mL] (Sigma) for 48 hours or treated
with 1 mg/ml of lipopolysaccharide (LPS) from E. coli (Sigma) for
20 hours, as an IFNc inducer. Total cellular RNA was extracted
from cells using Trizol reagent (Invitrogen, Burlington, ON,
Canada) according to the manufacturer’s protocol. Quantification
of RNA was performed with a Nanodrop (NanoDrop Technol-
ogies, Inc., Wilmington, Delaware, USA). 1 mg of total RNA was
reverse-transcribed using the QuantiTect reverse transcription kit
(Qiagen, Mississauga, ON, Canada). The cDNA was amplified
using the SsoFast EvaGreen Supermix kit (Bio-rad, Hercules, CA,
USA). The PCR amplification program for all cDNA consisted of
an enzyme activation step of 3 min at 98uC, followed by 40 cycles
of a denaturing step for 2 sec at 98uC and an annealing/extension
step for 5 sec at 57uC. The primers used for amplification of the
different target cDNA were previously described in Provost et al.,
2012 [19]. All primers were tested to achieve amplification
efficiency between 90% and 110%. The primer sequences were all
designed from the NCBI GenBank mRNA sequences using web-
based software primerquest from Integrated DNA technologies.
The Bio-Rad CFX-96 sequence detector apparatus was used for
the cDNA amplification. The quantification of differences between
the different groups was calculated using the 22DDCt method.
Beta-2 microglobulin (B2M) was used as the normalizing gene to
compensate for potential differences in cDNA amounts. The non-
infected PAMs and SJPL cells were used as the calibrator reference
in the analysis.
Statistical Analyses
A two-way ANOVA model, followed by Bonferroni post-hoc
tests (Graphpad PRISM Version 5.03 software) were used to
determine if a statistically significant difference exists between
infections performed in adherence and cytotoxicity assays. One-
way ANOVA model, followed by Tukey’s Multiple Comparison
Test (Graphpad PRISM) were used to determine if a statistically
significant difference exists between PRRSV titer (TCID50)
obtained in MARC-145, SJPL and PAM cells. Unpaired t tests
were used for the qRT-PCR statistical analysis. Differences were
considered statistically significant with a P,0.05.
Supporting Information
Figure S1 NOD1 and NOD2 inhibition effect on PRRSV
replication. Detection of the N viral protein in PRRSV infected
SJPL cells by immunofluorescence. SJPL cells were infected with
PRRSV MOI of 0.5 for 4 hours (B) and then treated with 100 mM
of C12-iE-DAP (a NOD1 ligand) (D), or 100 mM of L18-MDP (a
NOD2 ligand) (F) for 48 hours. Control are SJPL cells untreated
(A) treated only with 100 mM of C12-iE-DAP (C), or 100 mM of
L18-MDP (E) for 48 hours. White scale bar represents 200 mm.
Pictures were taken at 100X magnification.
(TIFF)
Figure S2 Antiviral activities of AppDapxIDapxIIC cell
culture supernatant fractions against PRRSV. Detection of
the N viral protein in PRRSV infected SJPL cells by immuno-
fluorescence. SJPL cells were untreated (A) or infected with 0.5
MOI of PRRSV for 4 hours (B) then incubated with .3 kDa (C),
or ,3 kDa (D), or .50 kDa (E), or ,50 kDa (F) fraction of
AppDapxIDapxIIC cell culture supernatant. White scale bar
represents 200 mm. Pictures were taken at 100X magnification.
(TIFF)
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